MedTrace Logo

Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

NCT07239596 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2026-03-16

No results posted yet for this study

Summary

This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

DRUG

SHR-8068；Adebrelimab ；Bevacizumab

SHR-8068+ Adebrelimab + Bevacizumab

DRUG

SHR-8068；Adebrelimab ；HS-10516

SHR-8068+ Adebrelimab +HS-10516

DRUG

SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516

SHR-8068+ Adebrelimab + Bevacizumab +HRS-10516

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-06
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07239596 on ClinicalTrials.gov